Britain and America have announced a landmark trade agreement that will maintain zero duties on UK pharmaceutical shipments going into the US market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to increase expenditure on medicines through the NHS. This move ensures that import taxes on these vital exports will be held at zero for a period of 36 months.
This deal is in response to recent threats to dramatically increase tariffs on patented drug imports, with increases floated reaching double the cost.
"This agreement with the United Kingdom bolsters the international landscape for cutting-edge drugs and establishes much-needed equity to transatlantic drug exports," a statement noted.
Commercial Importance
Medicines represent one of the Britain's most significant exports to the America, which is clearly the largest market for leading UK drugmakers.
Export figures indicate that in the 12 months prior to last September, the UK exported pharmaceutical products totaling over eleven billion pounds to the US. This amount accounted for 17.4% of all goods exports in that timeframe.
"This deal protects jobs, stimulates investment and facilitates the UK to establish itself as a global hub for medical research," a minister stated.
Detailed British Pledges
The pact involves several key changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase total public funding on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must return to the NHS to control costs will be restricted at fifteen percent. In the past, repayments topped 20%.
Recent Tensions
The pact takes place against a ongoing tension between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
These tensions were heightened by arguments that US consumers were charged a premium for the same drugs than consumers in the Britain and the EU.
Recently, several major drug company projects in the UK have been paused or scrapped, while major investments have been directed toward American operations.
A senior figure acknowledged that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a proportion of its resources over the previous ten-year period.
